Influenza-associated invasive aspergillosis in the ICU: a prospective, multicentre cohort study

Influenza-associated pulmonary aspergillosis (IAPA) can develop in critically ill patients with influenza in the intensive care unit (ICU), even in absence of classical risk factors. Thus far, most studies have been retrospective and the reported incidence has varied. Therefore, we set out to prospectively investigate IAPA incidence, potential risk factors and impact on patient outcomes. A prospective, multicentre observational cohort study was performed in the Netherlands and Belgium during three influenza seasons (2017–2020). Adult patients with PCR confirmed influenza or non-influenza community-acquired pneumonia (niCAP; control group) admitted to ICU with respiratory distress were included. Diagnosis of niCAP and mycological diagnostic work-up was at the treating physicians’ discretion. IAPA was defined according to the 2020 expert opinion case definition. Invasive aspergillosis occurred in 24% (34/140) of patients with influenza, compared to 13% (10/76) of patients with niCAP (p = 0.054) undergoing mycological diagnostic work-up and radiological imaging. IAPA was diagnosed at a median of 4 days after ICU admission. Patients with IAPA did not differ from those with influenza alone regarding presence of European Organization for Research and Treatment of Cancer/Mycosis Study Group Education and research Consortium (EORTC/MSGERC) host factors (9/32 [28%] versus 22/85 [26%], respectively; p = 0.82). They more frequently required invasive ventilatory support (26/29 [90%] versus 50/88 [57%], respectively; p = 0.001) and renal replacement therapy (15/33 [45%] versus 13/103 [13%], respectively; p < 0.001) in ICU. IAPA ICU mortality was significantly higher with 44% (15/34) compared to 14% (15/106) for influenza without aspergillosis (p < 0.001) and 17% (13/76) for niCAP. Non-survivors with IAPA were predominantly male (13/15 [87%] versus 9/19 [47%] survivors; p = 0.030) and more frequently received systemic corticosteroids in ICU (14/15 [93%] versus 10/19 [53%] survivors; p = 0.020). IAPA was an independent predictor of ICU mortality in patients with influenza (adjusted hazard ratio 1.99 [95% confidence interval 1.05 – 3.76; p = 0.035). We demonstrate prospectively that IAPA is a frequent complication in critically ill patients with influenza and that it is associated with high mortality and an adverse clinical course, rendering increased awareness among treating physicians imperative.

Authors

Institutions

Publication Details

Journal
Critical Care
Published
2025-11-29
DOI
https://doi.org/10.1186/s13054-025-05771-3
Citations
2
Primary Topic
Antifungal resistance and susceptibility
Type
article
Field-Weighted Citation Impact
2.79
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Influenza-associated invasive aspergillosis in the ICU: a prospective, multicentre cohort study

Eva Kolwijck, Oscar Hoiting, Jeroen Schouten, Nico Janssen et al.
2 citations
Critical Care
Antifungal resistance and susceptibility
2.79
article

Influenza-associated invasive aspergillosis in the ICU: a prospective, multicentre cohort study

Eva Kolwijck, Oscar Hoiting, Jeroen Schouten, Nico Janssen, Karin van Dijk, Birkitt L. ten Tusscher, Piet Lormans, Johan I. van der Spoel, Roger J. M. Brüggemann, Pieter Depuydt, Paul E. Verweij, Lore Vanderbeke, Joost Wauters, Heleen Aardema, Bart J. A. Rijnders, Dennis C. J. J. Bergmans, Marc Bourgeois, Katrien Lagrou, Frank L. van de Veerdonk, Simon Feys, Nicole P. Juffermans, Peter Messiaen, Charlotte H. S. B. van den Berg, Cato Jacobs
article en
2 citations

Abstract

Influenza-associated pulmonary aspergillosis (IAPA) can develop in critically ill patients with influenza in the intensive care unit (ICU), even in absence of classical risk factors. Thus far, most studies have been retrospective and the reported incidence has varied. Therefore, we set out to prospectively investigate IAPA incidence, potential risk factors and impact on patient outcomes. A prospective, multicentre observational cohort study was performed in the Netherlands and Belgium during three influenza seasons (2017–2020). Adult patients with PCR confirmed influenza or non-influenza community-acquired pneumonia (niCAP; control group) admitted to ICU with respiratory distress were included. Diagnosis of niCAP and mycological diagnostic work-up was at the treating physicians’ discretion. IAPA was defined according to the 2020 expert opinion case definition. Invasive aspergillosis occurred in 24% (34/140) of patients with influenza, compared to 13% (10/76) of patients with niCAP (p = 0.054) undergoing mycological diagnostic work-up and radiological imaging. IAPA was diagnosed at a median of 4 days after ICU admission. Patients with IAPA did not differ from those with influenza alone regarding presence of European Organization for Research and Treatment of Cancer/Mycosis Study Group Education and research Consortium (EORTC/MSGERC) host factors (9/32 [28%] versus 22/85 [26%], respectively; p = 0.82). They more frequently required invasive ventilatory support (26/29 [90%] versus 50/88 [57%], respectively; p = 0.001) and renal replacement therapy (15/33 [45%] versus 13/103 [13%], respectively; p < 0.001) in ICU. IAPA ICU mortality was significantly higher with 44% (15/34) compared to 14% (15/106) for influenza without aspergillosis (p < 0.001) and 17% (13/76) for niCAP. Non-survivors with IAPA were predominantly male (13/15 [87%] versus 9/19 [47%] survivors; p = 0.030) and more frequently received systemic corticosteroids in ICU (14/15 [93%] versus 10/19 [53%] survivors; p = 0.020). IAPA was an independent predictor of ICU mortality in patients with influenza (adjusted hazard ratio 1.99 [95% confidence interval 1.05 – 3.76; p = 0.035). We demonstrate prospectively that IAPA is a frequent complication in critically ill patients with influenza and that it is associated with high mortality and an adverse clinical course, rendering increased awareness among treating physicians imperative.

Critical Care
University Medical Center Groningen (NL), Radboud University Nijmegen (NL), Ghent University Hospital (BE), Erasmus MC (NL), Radboud University Medical Center (NL), University Medical Center Utrecht (NL), Maastricht University (NL), Jessa Hospital (BE), Radboud Institute for Molecular Life Sciences (NL), Laboratoire National de Référence (MA), Canisius-Wilhelmina Ziekenhuis (NL), AZ Sint-Jan (BE), AZ Delta (BE), Amsterdam University Medical Centers (NL), Hasselt University (BE), University of Amsterdam (NL), UCLouvain (BE), KU Leuven (BE)
Openalex Percentile: Top 8%
Antifungal resistance and susceptibility
2.79
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.